Menu
1 min read · estimated
APPROVED USE
What FDA approved
As a single agent for adults with relapsed or refractory follicular lymphoma after two or more systemic lines.
LAMPGEN ANALYSIS
Why it matters
FDA converted the 2024 accelerated single-agent indication to traditional approval in the same action that added a combination regimen.
What research teams should watch
Document prior systemic lines and ensure the order set uses the monotherapy schedule rather than the distinct combination schedule.
PRIMARY RECORDS